Iressa v BSC (Best Supportive Care) in First line NSCLC - INSTEP

Study identifier:1839IL/0711

ClinicalTrials.gov identifier:NCT00259064

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase II Multicentre Randomised, Parallel Group, Double-Blind, Placebo-Controlled Study of ZD1839 (IRESSATM) (250MG Tablet) Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Chemotherapy-Naive Patients with Advanced (Stage IIIB or IV) Non-Small Cell Lung Cancer (NSCLC) and Poor Performance Status

Medical condition

NSCLC

Phase

Phase 2/3

Healthy volunteers

No

Study drug

Gefitinib

Sex

All

Actual Enrollment

216

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 01 Sept 2004
Primary Completion Date: 01 Feb 2007
Study Completion Date: 01 Apr 2016

Study design

Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 May 2016 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria